Showing 3171-3180 of 5972 results for "".
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Cosmetic Surgery Forum Announces Innovators in Dermatology Recipientshttps://practicaldermatology.com/news/20131107-cosmetic_surgery_forum_announces_innovators_in_dermatology_recipients/2459420/The upcoming Cosmetic Surgery Forum (www.cosmeticsurgeryforum.com), taking place at the ARIA Resort and Casino in Las Vegas from December 5-7, recently announced the recipients of its “Innovators in Dermatology” presentation. Among those honored this year will be Jim Hartman, Vice President of US Ae
- Suneva Medical Announces Expansion Of Its ReGenica Distribution Partnership With Obagi Medical Productshttps://practicaldermatology.com/news/20131101-suneva_medical_announces_expansion_of_its_regenica_distribution_partnership_with_obagi_medical_product/2459424/Suneva Medical, Inc., recently announced plans to expand its existing partnership with Obagi Medical Products, Inc. Suneva Medical distributes, and is the exclusive licensee for, the full line of ReGenica skincare produ
- New Stelara Data Show Inhibition Of Joint Destruction In Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/20131029-new_stelara_data_show_inhibition_of_joint_destruction_in_psoriatic_arthritis_patients/2459427/New findings from two integrated Phase III Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with ustekinumab (Stelara) resulted in
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chro
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primarily
- Ellzey Coding Solutions Introduces ICD-10 for Dermatology Manualhttps://practicaldermatology.com/news/20131010-ellzey_coding_solutions_introduces_icd-10_for_dermatology_manual/2459440/Ellzey Coding Solutions, Inc., recently released an ICD-10 coding manual specifically for dermatologists. The 2014 ICD-10 for Dermatology program is a tool that can be used to prepare dermatologists and staff with what they need to know about the ICD-10-CM diagnosis coding syste
- Strathspey Crown's Alphaeon Acquires Toxin Developer Evolus, Inc.https://practicaldermatology.com/news/20131004-strathspey_crowns_alphaeon_acquires_toxin_developer_evolus_inc/2459443/Strathspey Crown Holdings, LLC has acquired Evolus, Inc. of Santa Barbara, California for an undisclosed amount. As part of the transaction, Strathspey Crown's wholly-owned subsidiary, Alph